Profile data is unavailable for this security.
About the company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
- Revenue in USD (TTM)25.48m
- Net income in USD-90.71m
- Incorporated2000
- Employees236.00
- LocationCellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
- Phone+33 181691600
- Fax+33 181691606
- Websitehttps://www.cellectis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | 0.00 | -44.81m | 206.76m | 14.00 | -- | -- | -- | -- | -0.7456 | -0.7456 | 0.00 | -0.9739 | 0.00 | -- | -- | 0.00 | -165.97 | -92.08 | -394.92 | -121.97 | -- | -- | -- | -- | -- | -12.72 | 6.24 | -- | -- | -- | -15.26 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 207.94m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.09m | 208.00m | 10.00 | -- | 2.29 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Trevi Therapeutics Inc | 0.00 | -29.07m | 208.26m | 25.00 | -- | 2.50 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Zevra Therapeutics Inc | 27.46m | -46.05m | 208.88m | 65.00 | -- | 3.23 | -- | 7.61 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 209.68m | 51.00 | -- | 0.757 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -66.86m | 210.16m | 58.00 | -- | 0.7565 | -- | -- | -1.19 | -1.19 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -21.20 | -- | -21.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 210.49m | 147.00 | -- | -- | -- | 1.80 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Generation Bio Co | 5.90m | -126.61m | 210.77m | 174.00 | -- | 1.03 | -- | 35.70 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Prelude Therapeutics Inc | 0.00 | -121.83m | 212.03m | 128.00 | -- | 0.894 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Cellectis SA (ADR) | 25.48m | -90.71m | 213.04m | 236.00 | -- | 1.46 | -- | 8.36 | -1.93 | -2.21 | 0.542 | 2.05 | 0.0852 | -- | 2.22 | 107,983.10 | -32.81 | -21.38 | -40.55 | -26.37 | -- | -61.60 | -385.36 | -268.89 | -- | -5.89 | 0.3871 | -- | -33.35 | -5.27 | -5.77 | -- | -14.21 | -- |
| Renovaro Inc | 0.00 | -41.23m | 215.50m | 12.00 | -- | 2.33 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Omeros Corp | 0.00 | -174.92m | 216.13m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 216.47m | 121.00 | -- | 1.27 | -- | 60.13 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Ovid Therapeutics Inc | 391.69k | -52.34m | 216.68m | 40.00 | -- | 2.46 | -- | 553.19 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 217.98m | -- | -- | 11.48 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Cellectis SA's reporting currency: US Dollar USD
13.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Long Focus Capital Management LLCas of 31 Dec 2023 | 4.49m | 6.25% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 1.85m | 2.58% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2023 | 1.44m | 2.01% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 827.25k | 1.15% |
| Principal Global Investors LLCas of 31 Mar 2024 | 424.53k | 0.59% |
| Macquarie Investment Management Business Trustas of 31 Dec 2023 | 226.88k | 0.32% |
| KBC Asset Management NVas of 31 Dec 2023 | 163.45k | 0.23% |
| Oppenheimer & Co., Inc. (Wealth Management)as of 31 Dec 2023 | 133.14k | 0.19% |
| Jackson National Asset Management LLCas of 31 Dec 2023 | 116.75k | 0.16% |
| LPL Financial LLCas of 31 Dec 2023 | 72.19k | 0.10% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
